Document:

Master Services Agreement between the Company and Arch Pharmalabs, Ltd.

 [*] Certain information in this document has been omitted and filed separately with the Securities and Exchange
Commission. Confidential treatment has been requested with respect to the omitted portions. 
 EXHIBIT 10.15 
 MASTER SERVICES AGREEMENT 
 This Master Services Agreement, dated August 1, 2006 (the “Agreement”), effective
as of August 1, 2006 (the “Effective Date”), is made and entered into by and between Codexis, Inc., a Delaware corporation, having a place of business at 200 Penobscot Drive, Redwood City, California 94063, USA, (“Codexis”)
and Arch Pharmalabs Limited, a corporation organized and existing under the laws of India, having a place of business at H wing, 4th Floor, Tex
Centre, Chandivali, Mumbai, 400072, India, (“Arch”). 
 WHEREAS, Arch provides services relating to chemical processes and
manufacturing methods; and 
 WHEREAS, Codexis is engaged in pharmaceutical business and desires to utilize the services of Arch to develop
chemical processes and manufacturing methods solely for use by Codexis. 
 NOW THEREFORE, in consideration of the foregoing and the covenants
and promises contained in this Agreement, the parties agree as follows: 
 1. Services: During the term of this Agreement, Arch shall
conduct chemical process and manufacturing method development services (the “Services”) for Codexis utilizing at least an average of [*] Arch full time equivalent employees (“FTE(s)”) per year in accordance with direction from
Codexis and protocol(s) agreed to by the parties in writing, each of which shall specify the particular services to be conducted and the goal of such activities, the number and type of FTE(s) devoted to such protocol, the time frame for conducting
such services, and other relevant matters (each a “Services Protocol”). Each Services Protocol shall reference and incorporate the terms of, and shall be attached as an exhibit to, this Agreement. In the event that any provision of a
Services Protocol contradicts this Agreement, this Agreement shall govern. All FTEs who perform Services under this Agreement shall have appropriate professional and technical training and expertise to conduct the Services. In the event that Codexis
requests that Arch remove a specific FTE assigned by Arch to perform its obligations under a Services Protocol, Arch shall use its best efforts to replace such FTE with an alternative FTE approved by Codexis. The scope of chemical process and
manufacturing method development included within each Services Protocol shall be defined in such Services Protocol and may be amended in writing by the parties from time to time during the term of this Agreement. Arch shall consult with Codexis
regarding all methods, reagents, protocols and the like, and Codexis shall have final approval authority over all aspects of the Services and Services Protocols. Arch shall not conduct activities relating to any compound within a Services Protocol
on its own behalf or any third party during the term of this Agreement or for a period of three (3) years thereafter. Arch will periodically, but not less than once per week, consult with Codexis and keep Codexis fully informed of the progress
of the Services. 
 2. Delivery: Arch shall deliver to Codexis deliverables as set forth in each Services Protocol, which may include,
for example, detailed descriptions of experimental 

 
methods, detailed process protocols, synthesized compounds, analytical methods for testing compounds, periodic status reports in addition to the Final Report
described in Section 5, and/or other analytical procedure data agreed to by the parties in the Services Protocol (the “Results”). For the purpose of clarification, “Results” shall include any compound prepared under a
Services Protocol. The parties shall confer prior to any such delivery of the Results. Title to all Results shall pass to Codexis free and clear of any security interest, lien, or other encumbrance. 
 3. Payments: As consideration for Arch’s performance of the Services during the term of this Agreement, Codexis shall pay to Arch the
following payments: (a) [*] within one hundred and eighty (180) days after the Effective Date; (b) [*] within one hundred and eighty (180) days after the first anniversary of the Effective Date; (c) [*] within thirty
(30) days after the second anniversary of the Effective Date; (d) [*] within one hundred and eighty (180) days after the second anniversary Effective Date; (e) [*] within thirty (30) days after the third anniversary of the
Effective Date; and (f) [*] within one hundred eighty (180) days after the third anniversary of the Effective Date. Such payments shall include all costs and expenses of Arch, including, for example, labor, facilities, analysis, packaging,
waste disposal, reports and delivery of the Results to Codexis. Such payments shall also be inclusive of all taxes, duties or levies of whatsoever in nature, including, for example, excise duty, sales tax, VAT, service tax, if any, levied in
connection with or arising out of performance of Services or any other obligation of Arch under this Agreement. Codexis shall have no obligation to reimburse Arch for any costs, tax, duties or levies and expenses of Arch in excess of such payment.
Arch shall also be responsible for all compliance requirements under the applicable laws in respect of its obligations under this Agreement, and any fines or penalties levied on account of any non-compliance shall be solely borne by Arch. If, in the
reasonable opinion of Codexis, Arch has failed to perform or complete its performance under a Services Protocol or this Agreement, upon a 15-day written notice to Arch by Codexis, Codexis shall have the right to delay or withhold payment until such
performance is complete and accepted by Codexis. 
 4. Materials and Equipment: Arch shall be responsible for the procurement, proper
quality and documentation of the quality of all materials, equipment, and facilities used to conduct the Services under this Agreement. 
 5.
Records: Arch shall prepare and maintain detailed laboratory notebook records of the preparation of the Results. Arch shall deliver to Codexis, not later than thirty (30) days following the completion of each Services Protocol, a final
report (the “Final Report”) including all information related to such Services Protocol. Arch shall prepare and deliver complete detailed analytical information requested by Codexis in writing for the purpose of preparing patent
applications. Codexis shall be free to disclose and use such information for any purpose and shall exclusively own all such information. Codexis may audit and copy such records, analytical data, and laboratory notebook records during Arch’s
normal business hours. 
  

 [*] Certain information in this document has been omitted and filed separately with the Securities and Exchange
Commission. Confidential treatment has been requested with respect to the omitted portions. 
 2 

 6. Best Efforts: Arch covenants to use best efforts, using no less than commonly accepted
professional standards of workmanship, to accomplish the goals and objectives of the Services conducted under the terms of this Agreement. Arch covenants to not utilize, without Codexis’ prior written consent, any process, device, intermediate,
reagent, or composition of matter in the performance of this Agreement that is not expressly set forth in the Services Protocol. 
 7.
Ownership and Licenses: Codexis shall own all intellectual property rights relating to the Results and, except as required to conduct the Services, Arch shall have no right or license in such intellectual property rights. Arch shall retain
ownership of intellectual property rights in analytical, manufacturing technologies employed and controlled by Arch (and not by Codexis) to perform its obligations under this Agreement; provided, however, that Arch hereby grants to Codexis an
irrevocable, perpetual, fully paid-up, royalty-free, worldwide, non-exclusive license, with the right to sublicense, under such intellectual property rights to make, use, sell, offer to sell, import, or export the Results. Codexis may disclose such
intellectual property rights in any patent applications filed by Codexis. 
 All information (a) received from Codexis pursuant to this
Agreement or (b) obtained as a result of Arch’s performance under this Agreement as defined in each Services Protocol (collectively, the “Information”) shall be the sole property of Codexis. Arch agrees to disclose promptly to
Codexis, and Codexis shall own, all inventions, discoveries, designs, innovations, improvements, and all other intellectual property rights made or perfected by Arch and/or Codexis in the performance of, or arising out of, the Services and/or the
use by Arch of any Information for which Arch has an obligation of confidentiality or nonuse under Section 8 (the “Discoveries”). Codexis shall have the sole right to file, prosecute, and maintain patent applications and patents in
respect of the Information, Discoveries, and/or Results. Arch hereby undertakes and agrees to execute and have its employees execute such assignments and other papers which, in the reasonable opinion of Codexis, are necessary at any time to permit
the filing and prosecution of applications for patents covering claiming Information, Discoveries, and/or the Results. Arch hereby further agrees that, at Codexis’ request and expense, Arch will assist Codexis in the preparation, filing, and
prosecution of such patent applications and patents. To the extent that Arch is or becomes aware that any of the Information, Discoveries, and/or Results are disclosed publicly, for example in an existing patent/patent application, it shall inform
Codexis. 
 8. Confidentiality: Arch shall maintain as confidential all Information, Discoveries, and/or the Results, and shall limit
access to Information, Discoveries, and/or Results to only those persons who, under Arch’s direct control, will be engaged in employing Information for the purposes of fulfilling Arch’s obligations under this Agreement and are under
obligations of non-use and nondisclosure no less protective than those set forth in this Agreement. At no time shall Information be employed for any purpose other than as described in the previous sentence or disclosed or provided to any third party
without the prior written consent of Codexis. The foregoing obligations of confidentiality and nonuse shall continue for [*] years after the termination of the 

  

 [*] Certain information in this document has been omitted and filed separately with the Securities and Exchange
Commission. Confidential treatment has been requested with respect to the omitted portions. 
 3 

 
Services corresponding to the Information, Discoveries, and/or the Results, or [*] years after the date of disclosure by Codexis if no Services Protocol
corresponding to the Information is agreed to by the parties. The foregoing obligations of confidentiality and nonuse shall not apply to Information (a) that was known to Arch prior to this Agreement as evidenced by its written records, except
Information that was known to Arch as a result of prior confidential disclosures to Arch by Codexis or work performed by Arch for Codexis; (b) that is or becomes generally available to the public by use, publication or the like, through no
fault of Arch; or (c) that is disclosed to Arch by a third party who has the legal right to disclose Information. Except as otherwise agreed to herein, if Arch is requested or required by law to disclose any Information, Discoveries, and/or
Results to an authorized government agency or to any other party, Arch shall immediately notify Codexis in writing of all details of the request or requirement and give Codexis sufficient opportunity to contest such request or requirement and/or
obtain an appropriate protective order prior to Arch making any such disclosure. Notwithstanding (a), (b), or (c) above, Information shall not be deemed to be within any of the exceptions merely because (i) it is specific but is embraced
by more general information coming within one of the exceptions, (ii) it is a combination of features for which the individual features come within one of the exceptions, or (iii) it is Information related to Information which comes within
one of the exceptions. 
 9. Term and Termination: 
 9.1 This Agreement shall begin on the Effective Date and expire four (4) years after the Effective Date unless terminated earlier pursuant to this Section 9. 
 9.2 Upon sixty (60) days’ notice from Codexis, Codexis shall have the right at any time to terminate this Agreement and/or the Services, in whole or
in part, prior to completion. Such termination by Codexis shall not relieve Codexis of its obligations under this Agreement to pay Arch under Section 3 on a pro rata basis for all work completed by Arch for Codexis prior to such termination
date; provided, however, such obligation to pay shall not exceed the price set forth in Section 3. 
 9.3 Either party may terminate
this Agreement at any time if the other party fails to perform any material obligation, covenant, condition, or limitation herein, provided such other party shall not have remedied its failure within sixty (60) days after receipt of written notice
from the terminating party of such failure. 
 9.4 Sections 2, 4–8, 9.4, and 10–23 shall survive expiration or termination of this
Agreement. 
 10. Indemnification: 
 10.1 Codexis Indemnity: Codexis shall indemnify and hold harmless Arch, its directors, officers, and employees, from and against any and all liability, damage, loss, cost (including reasonable attorneys’
fees), and expense resulting from claims of any kind and character by any third party (including, without limitation, 

  

 [*] Certain information in this document has been omitted and filed separately with the Securities and Exchange
Commission. Confidential treatment has been requested with respect to the omitted portions. 
 4 

 
employees or agents of Codexis) with respect to the Results supplied to Codexis pursuant to this Agreement. Notwithstanding the foregoing, Arch shall not be
entitled to indemnification under this Section 10.1 against any claim to the extent resulting from Arch’s negligence or willful misconduct or directly arising out of Arch’s performance of its obligations hereunder. 
 10.2 Arch Indemnity: Arch shall indemnify and hold harmless Codexis, its directors, officers, and employees, from and against any and all
liability, damage, loss, cost (including reasonable attorneys’ fees), and expense resulting from claims of any kind and character by any third party (including, without limitation, employees or agents of Arch) arising out of or in connection
with Arch’s performance under this Agreement, including, without limitation, liability, damage, loss, cost, and expense arising out of or in connection with the disposal of waste chemicals and solvents, and the failure to use materials,
equipment, and facilities of appropriate quality in conduct of the Services. Notwithstanding the foregoing, Codexis shall not be entitled to indemnification under this Section 10.2 against any claim to the extent resulting from Codexis’
negligence or willful misconduct in the course of Codexis’ performance of its obligations hereunder. 
 11. Limitation of
Liability: EXCEPT WITH RESPECT TO UNAUTHORIZED EXPLOITATION OF CODEXIS’ INTELLECTUAL PROPERTY RIGHTS OR BREACH OF THE CONFIDENTIALITY OBLIGATIONS UNDER THIS AGREEMENT, IN NO EVENT WILL ANY PARTY OR ANY OF ITS RESPECTIVE AFFILIATES BE LIABLE
TO THE ANY OTHER PARTY OR ANY OF ITS AFFILIATES FOR SPECIAL, INDIRECT, CONSEQUENTIAL, INCIDENTAL, EXEMPLARY, OR PUNITIVE DAMAGES, WHETHER IN CONTRACT, WARRANTY, TORT, NEGLIGENCE, STRICT LIABILITY, OR OTHERWISE. 
 12. Assignment: The parties recognize that the rights and obligations provided by Arch under this Agreement are unique and personal to Arch, and
thus Arch shall not assign this Agreement or any interest under this Agreement under any circumstances without Codexis’ consent, and any assignment by Arch without Codexis’ consent shall be null and void. Codexis, however, may assign this
Agreement or any interest under this Agreement without Arch’s consent. 
 13. Waiver: No provision of this Agreement shall be
waived by any act, omission or knowledge of a party or its agents or employees except by an instrument in writing expressly waiving such provision and signed by a duly authorized officer of the waiving party. A waiver by any party of any of the
terms and conditions of this Agreement in any instance will not be deemed or construed to be a waiver of such term or condition for the future, or of any subsequent breach of this Agreement. All rights, remedies, undertakings, obligations, and
agreements contained in this Agreement will be cumulative and none of them will be in limitation of any other remedy, right, undertaking, obligation, or agreement of either party. 
 14. Severability: Whenever possible, each provision of this Agreement will be interpreted in such manner as to be effective and valid under
applicable law, but if any 

  

 [*] Certain information in this document has been omitted and filed separately with the Securities and Exchange
Commission. Confidential treatment has been requested with respect to the omitted portions. 
 5 

 
provision of this Agreement is held to be prohibited by or invalid under applicable law, such provision will be ineffective only to the extent of such
prohibition or invalidity without invalidating the remainder of this Agreement. 
 15. Notices and Deliveries: Any notice, request,
delivery, approval, or consent required or permitted to be given under this Agreement will be in writing and will be deemed to have been sufficiently given if delivered in person, transmitted by telecopier (receipt verified) or by express courier
service (signature required) or ten (10) days after it was sent by registered letter, return receipt requested (or its equivalent), provided that no postal strike or other disruption is then in effect or comes into effect within two
(2) days after such mailing, to the party to which it is directed at its address or facsimile number shown below or such other address or facsimile number as such party will have last given by notice to the other party. 
 If to Codexis, addressed to: 
 Codexis, Inc. 
 200 Penobscot Drive 
 Redwood City, CA 94063

 United States of America 
 Attn.: [*] 
 Facsimile: [*] 
 If to
Arch, addressed to: 
 Arch Pharmalabs Limited 
 H wing, 4th Floor 
 Tex Centre 
 Off Saki Vihar Road 
 Chandivali, Mumbai-
400072 
 India 
 Attn.: [*]

 Facsimile: [*] 
 16.
Independent Contractors: The relationship between Codexis and Arch created by this Agreement is one of independent contractors and neither party shall have the power or authority to bind or obligate the other except as expressly set forth in
this Agreement. Arch shall use its own discretion and shall have complete and authoritative control over its employees and the details of performing its obligations under this Agreement. Any provisions in this Agreement which may appear to give
Codexis the right to direct or exercise a measure of control over Arch as to the details of performing its obligations under this Agreement shall be deemed to mean that Arch shall follow the desires of Codexis. However, such provisions will not
entitle Codexis to utilize Arch’s facilities or office space at its discretion or control. 
  

 [*] Certain information in this document has been omitted and filed separately with the Securities and Exchange
Commission. Confidential treatment has been requested with respect to the omitted portions. 
 6 

 17. No Third Party Beneficiaries: This Agreement is neither expressly nor impliedly made for the
benefit of any party other than those executing it. 
 18. Force Majeure: Neither party shall be liable for its failure to perform
hereunder as a result of any event of force majeure beyond the party’s reasonable control including, but not limited to, acts of God, fire, flood, wars, sabotage, civil strife or demonstrations, accidents, strikes, lockouts or other labor
disputes, shortages, government actions, or regulations, inability to obtain supplies, raw materials or transportation or preparation failure (other than due to operator error). If either party’s performance is prevented in whole or part by any
such event, such party shall be excused any of its obligations hereunder during the period of delay of performance resulting from such event. 
 19. Entire Agreement; Amendments: This Agreement constitutes and contains the entire understanding and agreement of the parties respecting the subject matter of this Agreement and cancels and supersedes any and all prior and
contemporaneous negotiations, correspondence, understandings, and agreements between the parties, whether oral or written, regarding such subject matter. No modification of this Agreement shall be effective unless made in writing and signed by a
duly authorized representative of each party. 
 20. Governing Law; Jurisdiction: This Agreement shall be governed by and interpreted
in accordance with the laws of the State of New York excluding conflict or choice of laws principles that would result in the application of the laws of any jurisdiction other than the State of New York. 
 21. Names: Both parties agree that they will not use the name of the other party or any of its personnel for promotional literature or advertising
without the prior written approval of the other party. 
 22. Compliance with Laws: Notwithstanding anything to the contrary contained
herein, all rights and obligations of the parties are subject to prior compliance with, and each party shall comply with, all U.S. and foreign export and import laws, regulations, and orders, and such other United States and foreign laws,
regulations, and orders as may be applicable, including obtaining all necessary approvals required by the applicable agencies of the governments of the United States and foreign jurisdictions. 
 23. Interpretation: The descriptive headings of this Agreement are for convenience only and shall be of no force or effect in construing or
interpreting any of the provisions of this Agreement. All references in this Agreement to the singular shall include the plural where applicable, and all references to gender shall include both genders and the neuter. Unless otherwise specified,
references in this Agreement to any section shall include all subsections in such section. All references to days in this Agreement shall mean calendar days, unless otherwise specified. 
  

 [*] Certain information in this document has been omitted and filed separately with the Securities and Exchange
Commission. Confidential treatment has been requested with respect to the omitted portions. 
 7 

 24. Counterparts: This Agreement and the Services Protocol(s) may be executed simultaneously in
any number of counterparts, any one of which need not contain the signature of more than one party but all such counterparts taken together will constitute one and the same agreement. 
 [Signature Page Follows] 
  

 [*] Certain information in this document has been omitted and filed separately with the Securities and Exchange
Commission. Confidential treatment has been requested with respect to the omitted portions. 
 8 

 IN WITNESS WHEREOF, the parties have caused this Agreement to be executed by
their respective duly authorized officers as of the Effective Date, each copy of which will for all purposes be deemed to be an original. 
  

									
	 CODEXIS, INC.
	 		 	ARCH PHARMALABS LIMITED
	 (“Codexis”)
	 		 	 (“Arch”)

					
	By:	 	 /s/ Robert S. Breuil
	 		 	By:	 	 /s/ Ajit Kamath

	Name:	 	 Robert S. Breuil
	 		 	Name:	 	 Ajit Kamath

	Title:	 	 CFO
	 		 	Title:	 	 CMD

  

 Exhibits 
 Service Protocols 
  
 [*] Certain
information in this document has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with respect to the omitted portions.Form of Transaction Support Agreement, dated as of August 1, 2008

 Exhibit 10.1 
 FORM OF TRANSACTION SUPPORT AGREEMENT 
 THIS TRANSACTION SUPPORT AGREEMENT (this
“Agreement”) is made and entered into as of August 1, 2008 by and between Cypress Semiconductor Corporation, a Delaware corporation (“Parent”), Copper Acquisition Corporation, a Delaware corporation and
wholly-owned subsidiary of Parent (“Acquisition Sub”) and the undersigned securityholder (“Stockholder”) of Simtek Corporation, a Delaware corporation (the “Company”). 
 W I T N E S S E T H: 
 WHEREAS,
Parent, Acquisition Sub and the Company have entered into an Agreement and Plan of Merger of even date herewith (as it may be amended from time to time, the “Merger Agreement”), which provides for, among other things, (i) an
offer by Acquisition Sub (the “Offer”) to pay Two Dollars and Sixty Cents ($2.60) in cash (the “Per Share Amount”) for each of the issued and outstanding shares of capital stock of the Company, and (ii) the
merger of Acquisition Sub with and into the Company (the “Merger”) pursuant to which all outstanding shares of capital stock of the Company will be converted into the right to receive the consideration set forth in the Merger
Agreement. 
 WHEREAS, as of the date hereof, Stockholder is the Beneficial Owner (as defined below) of the securities of the Company,
including shares of Company Capital Stock and/or options to purchase or otherwise acquire shares of Company Capital Stock and/or warrants to purchase shares of Company Capital Stock and/or any other rights to purchase or otherwise acquire shares of
Company Capital Stock (collectively, the “Company Securities”) as is indicated on the signature page of this Agreement. 
 WHEREAS, in consideration of the execution of the Merger Agreement by Parent and Acquisition Sub, Stockholder (in Stockholder’s capacity as such) is hereby agreeing to tender and vote the Shares (as defined below) in accordance with
the terms and conditions set forth herein. 
 NOW, THEREFORE, in consideration of the foregoing premises and the representations, warranties,
covenants and agreements set forth herein, as well as other good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged and accepted, and intending to be legally bound hereby, the parties hereto hereby agree as
follows: 
 1. Certain Definitions. All capitalized terms that are used but not defined herein shall have the respective meanings
ascribed to them in the Merger Agreement. For all purposes of and under this Agreement, the following terms shall have the following respective meanings: 
 (a) “Beneficially Own” or “Beneficial Ownership” with respect to any securities means having “beneficial ownership” of such securities as determined pursuant to Rule 13d-3
under the Exchange Act, including pursuant to any contract. A “Beneficial Owner” is a Person who Beneficially Owns securities. 
 (b) “Company Capital Stock” means any capital stock of the Company. 

 (c) “Expiration Date” shall mean the earliest to occur of (i) such date and time as
the Merger Agreement shall have been terminated pursuant to Section 7 thereof or (ii) such date and time as the Merger shall become effective in accordance with the terms and provisions of the Merger Agreement. 
 (d) “Shares” shall mean (i) all Company Securities Beneficially Owned by Stockholder as of the date hereof, and (ii) all
additional Company Securities, including any shares of Company Capital Stock issuable upon the exercise of any options and/or warrants and/or other rights to purchase or otherwise acquire Company Capital Stock, of which Stockholder acquires
Beneficial Ownership during the period from the date of this Agreement through the Expiration Date (including by way of stock dividend or distribution, split-up, recapitalization, combination, exchange of shares and the like). 
 (e) A Person shall be deemed to have effected a “Transfer” of a Share if such person directly or indirectly (i) sells, pledges,
encumbers, assigns, grants an option with respect to, transfers or disposes of such Share or any interest in such Share, or (ii) enters into a contract or agreement providing for the sale of, pledge of, encumbrance of, assignment of, grant of
an option with respect to, transfer of or disposition of such Share or any interest therein. 
 2. Transfer of Shares. 
 (a) Transfer Restrictions. Stockholder shall not Transfer or cause or permit any Transfer of any of the Shares other than to Acquisition Sub (or
Parent on Acquisition Sub’s behalf) pursuant to the Offer. 
 (b) Transfer of Voting Rights. Stockholder hereby agrees that, at
all times commencing with the execution and delivery of this Agreement until the Expiration Date, Stockholder shall not deposit, or permit the deposit of, any Shares in a voting trust, grant any proxy in respect of the Shares held by Stockholder, or
enter into any voting or similar agreement in contravention of the obligations of such Stockholder under this Agreement with respect to any of the Shares. 
 3. Agreement to Vote Shares. 
 (a) At every meeting of the Company Stockholders called, and at every
adjournment or postponement thereof, and on every action or approval by written consent of the Company Stockholders, Stockholder (in Stockholder’s capacity as a Company Stockholder) shall, or shall cause the holder of record on any applicable
record date to, vote the Shares: 
 (i) in favor of the adoption of the Merger Agreement (as it may be amended from time to time), and in
favor of each of the other transactions contemplated by the Merger Agreement; 
 (ii) against approval of any proposal made in opposition
to, or in competition with, consummation of the Offer, the Merger or any other transactions contemplated by the Merger Agreement; and 
  

 2 

 (iii) against any of the following actions (other than those actions that relate to the Offer, the
Merger and any other transactions contemplated by the Merger Agreement): (A) any merger, consolidation, business combination, sale of assets, or reorganization of the Company or any of its Subsidiaries, (B) any sale, lease or transfer of
any significant part of the assets of the Company or any of its Subsidiaries, (C) any reorganization, recapitalization, dissolution, liquidation or winding up of the Company or any of its Subsidiaries, (D) any material change in the
capitalization of the Company or any of its Subsidiaries, or the corporate structure of the Company or any of its Subsidiaries, or (E) any other action that is intended, or could reasonably be expected to, impede, interfere with, delay,
postpone, discourage or adversely affect the Offer, the Merger or any other transaction contemplated by the Merger Agreement. 
 (b) In the
event that a meeting of the Company Stockholders is held, Stockholder shall, or shall cause the holder of record on any applicable record date to, appear at such meeting or otherwise cause the Shares to be counted as present thereat for purposes of
establishing a quorum. 
 (c) Stockholder shall not enter into any contract or agreement with any Person to vote or give instructions in any
manner inconsistent with the terms of this Section 3. 
 4. Agreement to Tender. Stockholder shall tender (and shall not
withdraw), pursuant to and in accordance with the terms of the Offer, the Shares. No later than five (5) Business Days prior to the initial expiration date of the Offer, Stockholder shall (a) deliver to the depositary designated in the
Offer, (i) certificates representing the Shares, (ii) an “agent’s message” (or such other evidence, if any, as the depositary for the Offer may reasonably request) in the case of book-entry or uncertificated shares, and
(iii) all other documents or instruments required to be delivered pursuant to the terms of the Offer, and/or (b) instruct its broker or such other person who is the holder of record of any Shares to tender such Shares for exchange in the
Offer pursuant to the terms and conditions of the Offer. Stockholder shall not tender the Shares into any exchange or tender offer commenced by a Person other than Parent, Acquisition Sub or any other Subsidiary of Parent. 
 5. Agreement Not to Exercise Appraisal Rights. Stockholder shall not exercise any rights (including, without limitation, under Section 262 of
the Delaware General Corporation Law) to demand appraisal of any Shares that may arise with respect to the Merger. 
 6. Directors and
Officers. Notwithstanding any provision of this Agreement to the contrary, nothing in this Agreement shall limit or restrict Stockholder from acting in Stockholder’s capacity as an officer or director of the Company or voting in such
capacity in Stockholder’s sole discretion on any matter (it being understood that this Agreement shall apply to Stockholder solely in Stockholder’s capacity as a Company Stockholder and/or holder of options to purchase shares of Company
Capital Stock and/or holder of warrants or other rights to purchase or otherwise acquire shares of Company Capital Stock). 
 7.
Irrevocable Proxy. Concurrently with the execution of this Agreement, Stockholder shall deliver to Parent a proxy in the form attached hereto as Exhibit A (the “Proxy”), which shall be irrevocable to the fullest
extent permissible by applicable Legal Requirements, with respect to the Shares. 
  

 3 

 8. No Ownership Interest. Nothing contained in this Agreement shall be deemed to vest in Parent or
Acquisition Sub any direct or indirect ownership or incidence of ownership of or with respect to any Shares. All rights, ownership and economic benefits of and relating to the Shares shall remain vested in and belong to Stockholder, and neither
Parent not Acquisition Sub shall have authority to manage, direct, superintend, restrict, regulate, govern, or administer any of the policies or operations of the Company or exercise any power or authority to direct Stockholder in the voting of any
of the Shares, except as otherwise provided herein. 
 9. Representations and Warranties of Stockholder. Stockholder hereby represents
and warrants (in Stockholder’s capacity as a Company Stockholder and/or holder of options to purchase shares of Company Capital Stock and/or holder of warrants and/or other rights to purchase or otherwise acquire shares of Company Capital
Stock) to Parent and Acquisition Sub that: 
 (a) Power; Binding Agreement. Stockholder has full power and authority to execute and
deliver this Agreement and the Proxy, to perform Stockholder’s obligations hereunder and to consummate the transactions contemplated hereby. The execution, delivery and performance by Stockholder of this Agreement, the performance by
Stockholder of its obligations hereunder and the consummation by Stockholder of the transactions contemplated hereby have been duly and validly authorized by Stockholder and no other actions or proceedings on the part of Stockholder are necessary to
authorize the execution and delivery by it of this Agreement or the Proxy, the performance by Stockholder of its obligations hereunder or thereunder or the consummation by Stockholder of the transactions contemplated hereby or thereby. This
Agreement and the Proxy have been duly executed and delivered by Stockholder, and, assuming this Agreement constitutes a valid and binding obligation of Parent and Acquisition Sub, constitute a valid and binding obligation of Stockholder,
enforceable against Stockholder in accordance with their terms except as the same may be limited by bankruptcy, insolvency, reorganization, moratorium or similar Laws now or hereafter in effect relating to creditors’ rights generally and
subject to general principles of equity. 
 (b) No Conflicts. Except for filings that may be required under the Exchange Act and the
HSR Act, and any applicable foreign antitrust, competition or merger control laws and regulations, no filing with, and no permit, authorization, consent, or approval of, any Governmental Entity is necessary for the execution by Stockholder of this
Agreement and the Proxy, the performance by Stockholder of its obligations hereunder and thereunder and the consummation by Stockholder of the transactions contemplated hereby and thereby. None of the execution and delivery by Stockholder of this
Agreement or the Proxy, the performance by Stockholder of its obligations hereunder or thereunder or the consummation by Stockholder of the transactions contemplated hereby or thereby will (i) conflict with or result in any breach of any
organizational documents applicable to Stockholder, (ii) result in a violation or breach of, or constitute (with or without notice or lapse of time or both) a default (or give rise to any third party right of termination, cancellation, material
modification or acceleration) under any of the terms, conditions or provisions of any contract or obligation of any kind to which Stockholder is 

  

 4 

 
a party or by which Stockholder or any of Stockholder’s properties or assets may be bound, or (iii) violate any Legal Requirements applicable to
Stockholder or any of Stockholder’s properties or assets. 
 (c) Ownership of Shares. Stockholder (i) is the Beneficial
Owner of the Company Securities as indicated on the signature page to this Agreement, all of which are free and clear of any Liens, (except any Liens arising under securities Legal Requirements or arising hereunder), and (ii) does not own,
beneficially or otherwise, any Company Securities other than the Company Securities indicated on the signature page to this Agreement. 
 (d)
Voting Power. Stockholder has or will have sole voting power, sole power of disposition, sole power to issue instructions with respect to the matters set forth herein, and sole power to agree to all of the matters set forth in this Agreement,
in each case with respect to all of the Shares, with no limitations, qualifications or restrictions on such rights, subject to applicable securities Legal Requirements and the terms of this Agreement. Notwithstanding anything in this Agreement to
the contrary, nothing herein shall require Stockholder to exercise any option and/or warrant to purchase shares of Company Capital Stock. 
 (e) No Finder’s Fees. No broker, investment banker, financial advisor or other person is entitled to any broker’s, finder’s, financial adviser’s or other similar fee or commission in connection with the
transactions contemplated by the Merger Agreement or this Agreement based upon arrangements made by or on behalf of Stockholder in Stockholder’s capacity as such. 
 (f) Reliance by Parent. Stockholder understands and acknowledges that Parent is entering into the Merger Agreement in reliance upon Stockholder’s execution and delivery of this Agreement. 
 10. Certain Restrictions. Stockholder shall not, directly or indirectly, take any action that would make any representation or warranty of
Stockholder contained herein untrue or incorrect. 
 11. No Solicitation. Stockholder (in Stockholder’s capacity as such) shall
not, and shall not authorize or permit any of its directors, officers or other employees, controlled affiliates, or any investment banker, attorney or other advisor or representative retained by Stockholder (collectively,
“Representatives”) to, directly or indirectly, (i) solicit, initiate, or knowingly encourage, facilitate or induce the making, submission or announcement of, an Acquisition Proposal, (ii) furnish to any Person (other than
Parent, Acquisition Sub or any designees of Parent or Acquisition Sub) any non-public information relating to the Company or any of its Subsidiaries, or afford access to the business, properties, assets, books or records of the Company or any of its
Subsidiaries to any Person (other than Parent, Acquisition Sub or any designees of Parent or Acquisition Sub), an Acquisition Proposal, (iii) participate or engage in discussions or negotiations with any Person with respect to an Acquisition
Proposal, (iv) approve, endorse or recommend an Acquisition Proposal, (v) execute or enter into any letter of intent, memorandum of understanding or contract contemplating or otherwise relating to an Acquisition Transaction. Stockholder
shall immediately cease any and all existing activities, discussions or negotiations 

  

 5 

 
with any Persons conducted heretofore with respect to any Acquisition Proposal or Acquisition Transaction. Without limiting the generality of the foregoing,
Stockholder acknowledges and hereby agrees that any violation of the restrictions set forth in this Section 11 by Stockholder or any of its Representatives shall be deemed to be a breach of this Section 11 by Stockholder.
Stockholder (in Stockholder’s capacity as such) shall not enter into any letter of intent or similar document or any contract contemplating or otherwise relating to an Acquisition Proposal unless and until this Agreement is terminated pursuant
to its terms. 
 12. Disclosure. Subject to reasonable prior notice and approval (which shall not be unreasonably withheld or
delayed), Stockholder shall permit and hereby authorizes Parent to publish and disclose in all documents and schedules filed with the SEC, and any press release or other disclosure document that Parent determines to be necessary or desirable in
connection with the Offer, the Merger and any transactions related to thereto, Stockholder’s identity and ownership of Shares and the nature of Stockholder’s commitments, arrangements and understandings under this Agreement. 
 13. Consents and Waivers. 
 (a)
Stockholder (in Stockholder’s capacity as such) hereby gives any consents or waivers that are reasonably required for the consummation of the Merger under the terms of any contracts to which Stockholder is a party or pursuant to any rights
Stockholder may have. 
 (b) [For stockholder holding warrants to purchase Company Capital Stock] [Each Stockholder is a holder of
certain warrants to purchase Company Capital Stock as set forth on Schedule 1 hereto (the “Warrants”). Each Stockholder hereby acknowledges and agrees that, to the extent such Warrant remains unexercised at the time of the closing of the
Offer (the “Acceptance Time”), each Warrant shall, notwithstanding anything else to the contrary in such Warrants, cease to represent a right to acquire Company Capital Stock and, as of and following the Acceptance Time, the Warrants will
be cancelled and no consideration shall be payable by Parent, Acquisition Sub, the Company or the Surviving Corporation therefor. For the avoidance of doubt, when executed by the Stockholders, this Agreement shall constitute the written consent of
each Stockholder to the cancellation of the Warrants as described in this Section 13(b). Notwithstanding anything to the contrary set forth herein, if the Offer is not consummated, the consent provided in this Section 13(b) shall be void
and of no force and effect.] 
 (c) [For stockholders holding Company’s 2002 7.5% convertible debentures] [Each Stockholder
hereby consents to the Offer and the Merger, and forever relinquishes and waives all rights to require the Company to redeem the Company Debentures pursuant to Section 4 thereof. For the avoidance of doubt, when executed by the Stockholders,
this Agreement shall constitute the written consent to the Offer contemplated under Section 4(a) of the Company Debentures. Notwithstanding anything to the contrary set forth herein, if the Offer is not consummated, the consent provided in this
Section 13(c) shall be void and of no force and effect.] 
 14. Further Assurances. Subject to the terms and conditions of this
Agreement, Stockholder shall use commercially reasonable efforts to take, or cause to be taken, all actions, and to do, or cause to be done, all things necessary to fulfill Stockholder’s obligations under this Agreement. Stockholder, in
Stockholder’s capacity as a Company Stockholder, shall at all times publicly support the Offer and the Merger. 
  

 6 

 15. Legending of Shares. If so requested by Parent, Stockholder agrees that the Shares shall bear
a legend stating that they are subject to this Agreement and the Proxy. 
 16. Merger Agreement. Stockholder hereby acknowledges
receipt of, and has had an opportunity to read and understand and consult with independent counsel concerning, the Merger Agreement (including exhibits and schedules thereto). 
 17. Termination. This Agreement and the Proxy shall terminate and shall have no further force or effect as of the Expiration Date. Notwithstanding
the foregoing, nothing set forth in this Section 17 or elsewhere in this Agreement shall relieve either party hereto from any liability, or otherwise limit the liability of either party hereto, for any breach of this Agreement.

 18. Miscellaneous. 
 (a) Severability. Any term or provision of this Agreement that is invalid or unenforceable in any situation in any jurisdiction shall not affect the validity or enforceability of the remaining terms and provisions hereof or the
validity or enforceability of the offending term or provision in any other situation or in any other jurisdiction. If the final judgment of a court of competent jurisdiction declares that any term or provision hereof is invalid or unenforceable, the
parties hereto agree that the court making such determination shall have the power to limit the term or provision, to delete specific words or phrases or to replace any invalid or unenforceable term or provision with a term or provision that is
valid and enforceable and that comes closest to expressing the intention of the invalid or unenforceable term or provision, and this Agreement shall be enforceable as so modified. In the event such court does not exercise the power granted to it in
the prior sentence, the parties hereto agree to replace such invalid or unenforceable term or provision with a valid and enforceable term or provision that will achieve, to the extent possible, the economic, business and other purposes of such
invalid or unenforceable term. 
 (b) Assignment. This Agreement shall be binding upon, and shall be enforceable by and inure to the
benefit of, the parties hereto and their respective successors and assigns. This Agreement shall not be assignable by any party without the express written consent of the other parties hereto. 
 (c) Amendments. This Agreement may not be amended except by an instrument in writing signed on behalf of each of the parties hereto. 

(d) Specific Performance. Each of the parties hereto agrees that irreparable damage would occur in the event that any of the provisions of this
Agreement were not performed in accordance with their specific terms or were otherwise breached. It is accordingly agreed that, in addition to any other remedy that a party hereto may have under law or in equity, any party hereto shall be entitled
to seek injunctive relief to prevent any breach of this Agreement and to enforce specifically the terms and provisions hereof. 
  

 7 

 (e) Other Remedies. Except as otherwise provided herein, any and all remedies herein
expressly conferred upon a party will be deemed cumulative with and not exclusive of any other remedy conferred hereby, or by law or equity upon such party, and the exercise by a party of any one remedy will not preclude the exercise of any other
remedy. 
 (f) Notices. Any notice or other communication required or permitted to be delivered to any party under this Agreement
shall be in writing and shall be deemed properly delivered, given and received when delivered (by hand, by registered mail, by courier or express delivery service or by facsimile) to the address or facsimile telephone number set forth beneath the
name of such party below (or to such other address or facsimile telephone number as such party shall have specified in a written notice given to the other parties hereto): 
 if to Parent or Acquisition Sub: 
 Cypress Semiconductor Corporation 
 198 Champion Court 
 San Jose, CA 95134

 Attention: General Counsel 
 with a copy to: 
 Wilson Sonsini Goodrich & Rosati, Professional Corporation 
 650 Page Mill Road 
 Palo Alto, California
94304 
 Attention: Todd Cleary 
 Facsimile No.: (650) 493-6811 
 if to Stockholder: 
 to the address set forth on the signature page hereto. 
 (g) Waiver. 
 (i) No failure on the part of any party to exercise any power, right, privilege or
remedy under this Agreement, and no delay on the part of any party in exercising any power, right, privilege or remedy under this Agreement, shall operate as a waiver of such power, right, privilege or remedy; and no single or partial exercise of
any such power, right, privilege or remedy shall preclude any other or further exercise thereof or of any other power, right, privilege or remedy. 
 (ii) No party shall be deemed to have waived any claim arising out of this Agreement, or any power, right, privilege or remedy under this Agreement, unless the waiver of such claim, power, right, privilege or remedy is expressly set forth
in a written instrument duly executed and delivered on behalf of such party; and any such waiver shall not be applicable or have any effect except in the specific instance in which it is given. 
  

 8 

 (h) No Third Party Beneficiaries. Nothing in this Agreement, express or implied, is intended to or
shall confer upon any Person, other than the parties hereto, any right, benefit or remedy of any nature. 
 (i) Applicable Law;
Jurisdiction. This Agreement is made under, and shall be governed, construed and enforced in accordance with, the laws of the State of Delaware applicable to agreements made and to be performed solely therein, without giving effect to principles
of conflicts of law. In any action among or between any of the parties arising out of or relating to this Agreement, each of the parties irrevocably and unconditionally consents and submits to the exclusive jurisdiction and venue of any state or
federal court located within New Castle County, the State of Delaware and unconditionally consents to service of process in any such action by notice in accordance with Section 18(f). 
 (j) WAIVER OF JURY TRIAL. EACH OF PARENT, THE COMPANY AND ACQUISITION SUB HEREBY IRREVOCABLY WAIVES ALL RIGHT TO TRIAL BY JURY IN ANY ACTION,
PROCEEDING OR COUNTERCLAIM (WHETHER BASED ON CONTRACT, TORT OR OTHERWISE) ARISING OUT OF OR RELATING TO THIS AGREEMENT OR THE ACTIONS OF PARENT, COMPANY OR ACQUISITION SUB IN THE NEGOTIATION, ADMINISTRATION, PERFORMANCE AND ENFORCEMENT HEREOF.

 (k) Entire Agreement. This Agreement and the Proxy constitute the entire agreement and supersede all prior agreements and
understandings, both written and oral, among or between any of the parties with respect to the subject matter hereof. 
 (l) Certain
Interpretations. 
 (i) The parties hereto agree that any rule of construction to the effect that ambiguities are to be resolved against
the drafting party shall not be applied in the construction or interpretation of this Agreement. 
 (ii) As used in this Agreement, the
words “include” and “including,” and variations thereof, shall not be deemed to be terms of limitation, but rather shall be deemed to be followed by the words “without limitation.” 
 (iii) Except as otherwise indicated, all references in this Agreement to “Sections,” “Exhibits,” “Annexes” and
“Schedules” are intended to refer to Sections of this Agreement and Exhibits, Annexes and Schedules to this Agreement. 
 (m)
Expenses. All fees and expenses incurred in connection with this Agreement and the transactions contemplated hereby shall be paid by the party incurring the expenses, whether or not the Offer and the Merger are consummated. 
 (n) Counterparts. This Agreement may be executed in several counterparts, each of which shall be deemed an original and all of which shall
constitute one and the same instrument. 
  

 9 

 [Remainder of Page Intentionally Left Blank] 
  

 10 

 IN WITNESS WHEREOF, the undersigned have caused this Agreement to be duly executed to be effective as of
the date first above written. 
  

									
	CYPRESS SEMICONDUCTOR CORPORATION	 		 	STOCKHOLDER:
			
		 		 	  

		 		 		 	(Name of Entity, if an entity)
					
	By:	 	  
	 		 	By:	 	  

	Name:	 	  
	 		 	Name:	 	  

	Title:	 	  
	 		 	Title:	 	  

		 		 		 	Address:	 	
				
		 		 		 	  

		 		 		 	Facsimile:	 	  

				
		 		 		 	Share that are Beneficially Owned:
				
	COPPER ACQUISITION CORPORATION	 		 		 	
		 		 		 	                                 shares of Company
	By:	 	  
	 		 	Common Stock
	Name:	 	  
	 		 		 	
	Title:	 	  
	 		 		 	
		 		 		 	                                 shares of Company Common Stock issuable
upon exercise of outstanding options or warrants and/or other rights to purchase or otherwise acquire Company Common Stock

 (SIGNATURE PAGE TO TRANSACTION SUPPORT AGREEMENT) 

 EXHIBIT A 
 IRREVOCABLE PROXY 
 The undersigned securityholder (“Stockholder”) of Simtek Corporation, a Delaware
corporation (the “Company”), hereby irrevocably (to the fullest extent permitted by law) appoints                      and
                     of Cypress Semiconductor Corporation, a Delaware Corporation (“Parent”), and each of them, as the sole
and exclusive attorneys and proxies of the undersigned, with full power of substitution and resubstitution, to vote and exercise all voting and related rights (to the full extent that the undersigned is entitled to do so) with respect to all of the
shares of capital stock of the Company that now are or hereafter may be beneficially owned by the undersigned, and any and all other shares or securities of the Company issued or issuable to Stockholder on or after the date hereof (collectively, the
“Shares”) in accordance with the terms of this Irrevocable Proxy until the Expiration Date (as defined below). Upon Stockholder’s execution of this Irrevocable Proxy, any and all prior proxies given by Stockholder with respect
to any Shares are hereby revoked and Stockholder agrees not to grant any subsequent proxies with respect to the Shares until after the Expiration Date. 
 This Irrevocable Proxy is irrevocable to the fullest extent permitted by law, is coupled with an interest and is granted pursuant to that certain Transaction Support Agreement of even date herewith by and among Parent
and Stockholder (the “Transaction Support Agreement”), and is granted in consideration of Parent and Copper Acquisition Corporation, a Delaware corporation (“Acquisition Sub”), entering into that certain Agreement
and Plan of Merger of even date herewith (the “Merger Agreement”), among Parent, Acquisition Sub and the Company. The Merger Agreement provides for, among other things, (i) an offer by Acquisition Sub (the
“Offer”) to pay Two Dollars Sixty Cents ($2.60) in cash (the “Per Share Amount”) for each of the issued and outstanding shares of capital stock of the Company and (ii) the merger of Acquisition Sub with and
into the Company, pursuant to which all outstanding shares of capital stock of the Company will be converted into the right to receive the consideration set forth in the Merger Agreement. 
 As used herein, the term “Expiration Date” shall mean the earlier to occur of (i) such date and time as the Merger Agreement shall
have been terminated pursuant to Section 7 thereof and (ii) such date and time as the Merger shall become effective in accordance with the terms and provisions of the Merger Agreement. 
 The attorneys and proxies named above, and each of them, are hereby authorized and empowered by Stockholder, at any time prior to the Expiration Date, to
act as the undersigned’s attorney and proxy to vote the Shares, and to exercise all voting, consent and similar rights of Stockholder with respect to the Shares (including, without limitation, the power to execute and deliver written consents)
at every meeting of the Company Stockholders called, and at every adjournment or postponement thereof, and on every action or approval by written consent of the Company Stockholders: (i) in favor of the adoption of the Merger Agreement (as it
may be amended from time to time), and in favor of each of the other actions contemplated by the Merger Agreement; (ii) against approval of any proposal made in opposition to, or in competition with, consummation of the Offer, the Merger or any
other transactions contemplated by the 

 
Merger Agreement; and (iii) against any of the following actions (other than those actions that relate to the Offer, the Merger and any other
transactions contemplated by the Merger Agreement): (A) any merger, consolidation, business combination, sale of assets, or reorganization of the Company or any of its subsidiaries, (B) any sale, lease or transfer of any significant part
of the assets of the Company or any if its subsidiaries, (C) any reorganization, recapitalization, dissolution, liquidation or winding up of the Company or any of its subsidiaries, (D) any material change in the capitalization of the
Company or any of its subsidiaries, or the corporate structure of the Company or any of its subsidiaries, or (E) any other action that is intended, or could reasonably be expected to, impede, interfere with, delay, postpone, discourage or
adversely affect the Offer, the Merger or any other transactions contemplated by the Merger Agreement. 
 The attorneys and proxies named
above may not exercise this Irrevocable Proxy on any other matter except as provided herein. Stockholder may vote the Shares on all other matters. 
 Any obligation of Stockholder hereunder shall be binding upon the successors and assigns of Stockholder. 
 This Irrevocable Proxy
shall terminate, and be of no further force and effect, automatically upon the Expiration Date. 
  

					
	Dated:                     , 2008	 	STOCKHOLDER:
		
		 	  

		 	(Name of Entity, if an entity)
			
		 	By:	 	  

		 	Name:	 	  

		 	Title:	 	  

 (SIGNATURE PAGE TO IRREVOCABLE PROXY)

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00145-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00145-of-00352.parquet"}]]